R. De and L. , 68 1. Les patients étudiés pour l'analyse semi-quantitative, p.69

S. Darcourt, J. Booij, J. Tatsch, K. Varrone, A. et al., EANM procedure guidelines for brain neurotransmission SPECT using (123)I- labelled dopamine transporter ligands, Eur J Nucl Med Mol Imaging. févr, vol.10737, issue.1 22, pp.443-50, 2010.
DOI : 10.1007/s00259-009-1267-x

URL : http://doi.org/10.1007/s00259-009-1267-x

K. Van-laere, A. Varrone, J. Booij, V. Borght, T. Nobili et al., EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2, European Journal of Nuclear Medicine and Molecular Imaging, vol.36, issue.Pt 3, pp.434-476, 2010.
DOI : 10.1007/s00259-009-1265-z

D. Gupta and A. Kuruvilla, Vascular parkinsonism: what makes it different?, Postgraduate Medical Journal, vol.87, issue.1034, pp.829-865, 1034.
DOI : 10.1136/postgradmedj-2011-130051

J. Corvol and S. Hunot, Maladie de Parkinson, thématiques, neurosciencessciences-cognitives-neurologie-psychiatrie, Inserm.fr. févr, 2015.

S. Fahn, Parkinson's disease: 10 years of progress, 1997-2007, Movement Disorders, vol.7, issue.Suppl, pp.2-14, 1997.
DOI : 10.1002/mds.22796

A. Elbaz, J. Clavel, P. Rathouz, F. Moisan, J. Galanaud et al., Professional exposure to pesticides and Parkinson disease, Annals of Neurology, vol.13, issue.suppl 2, pp.494-504, 2009.
DOI : 10.1002/ana.21717

J. Darcourt, A. Schiazza, N. Sapin, M. Dufour, M. Ouvrier et al., 18F- FDOPA PET for the diagnosis of parkinsonian syndromes, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Radiopharm Chem Biol. déc, vol.58, issue.4, pp.355-65, 2014.

K. Leenders, A. Palmer, N. Quinn, J. Clark, G. Firnau et al., Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography., Journal of Neurology, Neurosurgery & Psychiatry, vol.49, issue.8, pp.853-60, 1986.
DOI : 10.1136/jnnp.49.8.853

G. Firnau, E. Garnett, R. Chirakal, S. Sood, C. Nahmias et al., [18F]Fluoro-l-dopa for the in vivo study of intracerebral dopamine, International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, vol.37, issue.8, pp.669-75, 1986.
DOI : 10.1016/0883-2889(86)90260-1

R. Guignard, A. Schiazza, A. Ochin, and J. Darcourt, Quantification de l???activit?? dopaminergique striatale en TEP ?? la 18F-DOPA??: quels param??tres choisir en routine???, M??decine Nucl??aire, vol.38, issue.2, pp.91-100, 2014.
DOI : 10.1016/j.mednuc.2014.01.002

D. Scherman, C. Desnos, F. Darchen, P. Pollak, F. Javoy-agid et al., Striatal dopamine deficiency in parkinson's disease: Role of aging, Annals of Neurology, vol.2, issue.4, pp.551-558, 1989.
DOI : 10.1002/ana.410260409

P. Jokinen, H. Helenius, E. Rauhala, A. Brück, O. Eskola et al., Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach, J Nucl Med Off Publ Soc Nucl Med. juin J Nucl Med Off Publ Soc Nucl Med. oct, vol.5043, issue.1510, pp.893-91324, 2002.

I. Chang, K. Lue, H. Hsieh, S. Liu, C. Kao et al., Automated striatal uptake analysis of 18F-FDOPA PET images applied to Parkinson's disease patients Brooks DJ. The early diagnosis of parkinson's disease Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy, 18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse. 1 juin, pp.796-803547, 1990.

A. Brück, S. Aalto, E. Rauhala, J. Bergman, R. Marttila et al., -dopa PET study A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen NOnlinear progression of parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa f 18 activity, Mov Disord Off J Mov Disord Soc. juill Mov Disord Off J Mov Disord Soc. 15 mai Arch Neurol. 1 mars, vol.162462, issue.223, pp.608-151009, 2001.

N. Pavese, M. Rivero-bosch, S. Lewis, A. Whone, D. Brooks et al., Clinical and [18F] dopa PET findings in early Parkinson's disease 6- [18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography Comparison of FP- CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism, Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study 30. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data, pp.1463-1471, 1993.

M. Ghaemi, R. Hilker, R. J. Sobesky, J. Heiss, W. Salmon et al., Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration, J Neurol Neurosurg Psychiatry. nov J Neurol. déc, vol.73246, issue.512, pp.517-231151, 1999.

N. Turjanski, A. Lees, and D. Brooks, Dopaminergic function in patients with posttraumatic parkinsonism: An 18F-dopa PET study, Neurology, vol.49, issue.1, pp.183-192, 1997.
DOI : 10.1212/WNL.49.1.183

X. Hu, N. Okamura, H. Arai, M. Higuchi, T. Matsui et al., 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies, Neurology, vol.55, issue.10, pp.1575-1582, 2000.
DOI : 10.1212/WNL.55.10.1575

J. Klein, C. Eggers, E. Kalbe, S. Weisenbach, C. Hohmann et al., Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivoClinical utility of (18)F-DOPA-PET in movement disorders. A systematic review], Neurology. 16 mars Puñal-Riobóo J Rev Esp Med Nucl. juin, vol.7428, issue.373, pp.885-92106, 2009.

J. Langston, E. Langston, and I. Irwin, MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects, Acta Neurol Scand Ribeiro M-J, Vidailhet M, vol.100, issue.39, pp.49-54, 1984.

R. Nandhagopal, L. Kuramoto, M. Schulzer, E. Mak, J. Cragg et al., Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease, Arch Neurol. avr Brain J Neurol. nov, vol.59134, issue.40, pp.580-63290, 2002.

C. Lee, A. Samii, V. Sossi, T. Ruth, M. Schulzer et al., In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease, Annals of Neurology, vol.163, issue.4, pp.493-503, 2000.
DOI : 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4

O. Aupee, G. Bonardel, O. Gontier, F. Montravers, E. Delong et al., Guide pour la rédaction de protocoles pour la tomographie par émission de positons (TEP) à la 6-fluoro-[18F]- L-dihydroxyphénylalanine ou 6-f luoro-[18F]-L-DOPA ([18F]-FDOPA) Soc Fr Med Nucl 2011. 43 Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics. 1 sept, vol.44, issue.3, pp.837-882, 1988.

J. Booij, T. Marina, A. J. , B. Henk, W. Pet et al., Clinical Applications of [123I]FP-CIT SPECT Imaging Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration, BMC Neurol. 1 sept Brain. 11 janv, vol.7134, issue.111, pp.27-463146, 2007.

R. Kuriakose, A. Stoessl, S. Fahn, D. Oakes, I. Shoulson et al., Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications Levodopa and the progression of Parkinson's disease Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study, Prog Brain Res. N Engl J Med. 9 déc J Neurol Neurosurg Psychiatry. juin, vol.18435183, issue.496, pp.177-922498, 2004.

K. Seifert and J. Wiener, The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes, Am J Neurodegener Dis. Mov Disord Off J Mov Disord Soc. oct Clin Nucl Med. mai, vol.21940, issue.525, pp.29-341175, 2004.

P. Gantet and . Ge, Quantification auto-calibr??e de la neurotransmission dopaminergique en TEMP??: ??valuation de DaTsoft3D, M??decine Nucl??aire, vol.38, issue.3, pp.133-54, 2014.
DOI : 10.1016/j.mednuc.2014.03.024

L. Oehme, M. Perick, B. Beuthien-baumann, M. Wolz, A. Storch et al., Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson???s disease, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease, pp.1550-1559, 2011.
DOI : 10.1007/s00259-011-1819-8

S. Kish, K. Shannak, and O. Hornykiewicz, Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications, Brain J Neurol. août N Engl J Med. 7 avr, vol.122318, issue.5614, pp.1437-48876, 1988.

G. Sawle, E. Playford, D. Burn, V. Cunningham, and D. Brooks, Separating Parkinson's Disease From Normality, Archives of Neurology, vol.51, issue.3, pp.237-280, 1994.
DOI : 10.1001/archneur.1994.00540150027011

D. Eidelberg, S. Takikawa, V. Dhawan, T. Chaly, W. Robeson et al., Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab)F-DOPA PET and cognition in de novo Parkinson's disease, sept Brain Eur J Nucl Med Mol Imaging. juin, vol.1342, issue.5187, pp.881-81062, 1993.